Table 3.
Comparisons at Month 3 in the Four Treatment Groups
| |
Group |
|
|||
|---|---|---|---|---|---|
| Characteristic | CSII alone | CSII+TZD | CSII+MET | CSII+ALA | P value |
| Weight (kg) | 65.7±8.3 | 69.0±12.0 | 68.0±11.5 | 64.2±10.5 | 0.306 |
| Waist (cm) | 83.1±6.0 | 85.3±9.7 | 85.8±7.1 | 84.0±7.7 | 0.429 |
| Waist/hip ratio (%) | 87.8±4.4 | 88.7±7.5 | 89.8±4.0 | 90.9±5.0 | 0.193 |
| HbA1c (%) | 6.4±0.5 | 6.5±0.8 | 6.2±0.5 | 6.9±0.8 | 0.001a |
| FPG (mmol/L) | 5.9±0.9 | 6.1±1.2 | 5.6±1.0 | 6.7±1.4 | 0.006a |
| AIR (pmol/L·10 min) | 88.2 (83.7) | 85.6 (193.0) | 134.7 (137.3) | 42.9±54.6 | 0.004a |
| HOMA-B | 80.6 (55.4) | 68.2 (74.1) | 93.9 (66.9) | 56.9 (36.4) | 0.011a |
| HOMA-IR | 2.32 (2.16) | 2.05 (1.55) | 1.99 (2.32) | 2.24 (1.90) | 0.819 |
Data are mean±SD values. Non-normally distributed variants such as acute insulin response (AIR), homeostasis model assessment of β-cell function (HOMA-B), and homeostasis model assessment of insulin resistance (HOMA-IR) were expressed as median (interquartile range) values and were logarithmically transformed before comparison.
a
One-way analysis of variance was used to compare the differences among groups. P<0.05 was considered significant.
ALA, α-lipoic acid; CSII, continuous subcutaneous insulin infusion; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; MET, metformin; TZD, thiazolidinedione.